Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro.
1. The effects of insulin-like growth factor I (IGF-I) on the rates of glucose transport and utilization and its interaction with insulin were investigated in rat soleus muscle in vitro. IGF-I increased the rates of glucose transport, lactate formation, glycogen synthesis and the flux of glucose to hexose monophosphate, but it had no effect on the rate of glucose oxidation or glycogenolysis. 2. In the absence of insulin, low levels of IGF-I (0-30 ng/ml) increased the rate of glycolysis and the content of fructose 2,6-bisphosphate, but the content of glucose 6-phosphate remained unaltered; at higher levels of IGF-I (300-3000 ng/ml) the rate of glycolysis and the content of fructose 2,6-bisphosphate showed a further modest increase, but the content of glucose 6-phosphate doubled. Similar changes were seen when the level of insulin was increased from basal (0-0.4 ng/ml) to maximal (40 ng/ml). 3. Neither IGF-I nor insulin affected the contents of ATP, ADP, AMP, phosphocreatine or citrate. 4. Maximal concentrations of IGF-I increased the rate of lactate formation to a greater extent than did maximal concentrations of insulin. 5. In the presence of IGF-I, the rate of glucose utilization was less responsive to insulin. 6. The results suggest that, in rat skeletal muscle: (a) IGF-I increases the rates of glucose transport and utilization independently of insulin, and has a preferential effect on the rate of lactate formation; (b) the effects of IGF-I and insulin are not additive; (c) in addition to its effects on glucose transport, IGF-I increases the rate of glycogen synthesis and may stimulate glycolysis at the level of 6-phosphofructokinase; (d) changes in the content of fructose 2,6-bisphosphate may be part of the mechanism to regulate glycolytic flux in skeletal muscle in response to either IGF-I or insulin.
Dimitriadis
G
G
Department of Biochemistry, University of Oxford, U.K.
Parry-Billings
M
M
Bevan
S
S
Dunger
D
D
Piva
T
T
Krause
U
U
Wegener
G
G
Newsholme
E A
EA
D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D005635:Fructosediphosphates / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D019298:Glucose-6-Phosphate; D005958:Glucosephosphates / Q000378:metabolism; D006003:Glycogen / Q000096:biosynthesis / Q000378:metabolism; D006019:Glycolysis; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D010766:Phosphorylation; D051381:Rats; D011919:Rats, Inbred Strains
D005635:Fructosediphosphates; D005958:Glucosephosphates; D007328:Insulin; D019298:Glucose-6-Phosphate; D007334:Insulin-Like Growth Factor I; C027652:fructose 2,6-diphosphate; D006003:Glycogen; D005947:Glucose